{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:15:45Z","timestamp":1790655345109,"version":"4.1.0"},"reference-count":87,"publisher":"Ovid Technologies (Wolters Kluwer Health)","license":[{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"crossref","award":["I01 BX001958"],"award-info":[{"award-number":["I01 BX001958"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"crossref","award":["CTSC004-12"],"award-info":[{"award-number":["CTSC004-12"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"crossref","award":["3UL1TR001449-08S1"],"award-info":[{"award-number":["3UL1TR001449-08S1"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"crossref","award":["I01 BX006187"],"award-info":[{"award-number":["I01 BX006187"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["CJASN"],"abstract":"<jats:p>In ideal situations, contrast agents used in radiologic procedures should provide sufficient image enhancement without high doses and without eliciting any adverse effects. Regrettably, this has not been the case, particularly in states of kidney disease. Standard use, and oftentimes contrast overuse, has highlighted the risk of developing nephrogenic systemic fibrosis and gadolinium toxicity from gadolinium-based contrast agents. Conflicting reports lead to confusion regarding the types of agents that cause injury, the overall injury rates, acceptable defining terms, and even which patient population is most at risk. This confusion can lead to withholding contrast-enhanced examinations in patients for fear of kidney injury. However, at the other end of the spectrum, many providers question the risk or reality of complications, citing conflicting reports. In truth, the risk of complications lies somewhere in between. Educated patients are knowledgeable about the risks associated with gadolinium-based contrast agent administrations, but many of their concerns are often dismissed by health care providers. Transparency is key because there is still much to learn about the overall risk of gadolinium exposures in states of kidney disease and normal kidney function. A learned provider will be foundational for mitigating patient concerns. To provide a foundational understanding of the risks associated with gadolinium exposure, this review focuses on the complications of gadolinium-based contrast agents.<\/jats:p>","DOI":"10.2215\/cjn.0000001115","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T21:00:09Z","timestamp":1779138009000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Gadolinium-Based Contrast Agents and the Theater of Safety"],"prefix":"10.2215","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6821-2067","authenticated-orcid":false,"given":"Joshua","family":"DeAguero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7063-0142","authenticated-orcid":false,"given":"Brent","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,5,18]]},"reference":[{"issue":"1","key":"B2-20260618","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1186\/s12916-024-03537-2","article-title":"Differences in hypersensitivity reactions and gadolinium deposition disease\/symptoms associated with gadolinium exposure to gadolinium-based contrast agents: new insights based on global databases VigiBase, FAERS, and IQVIA-MIDAS","volume":"22","author":"Qu","year":"2024","journal-title":"BMC Med."},{"issue":"6","key":"B3-20260618","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.3390\/ijerph18063000","article-title":"Nephrogenic systemic fibrosis as a complication after gadolinium-containing contrast agents: a rapid review","volume":"18","author":"Lange","year":"2021","journal-title":"Int J Environ Res Public Health."},{"issue":"9","key":"B4-20260618","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1055\/a-1328-3177","article-title":"Gadolinium-based contrast agents: what we learned from acute adverse events, nephrogenic systemic fibrosis and brain retention","volume":"193","author":"B\u00e4uerle","year":"2021","journal-title":"Rofo."},{"key":"B5-20260618","doi-asserted-by":"crossref","first-page":"100503","DOI":"10.1016\/j.ejro.2023.100503","article-title":"Gadolinium contrast agents- challenges and opportunities of a multidisciplinary approach: literature review","volume":"11","author":"Iyad","year":"2023","journal-title":"Eur J Radiol Open."},{"issue":"4","key":"B6-20260618","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.mric.2017.06.006","article-title":"Gadolinium-based contrast agents: associated adverse reactions","volume":"25","author":"Ramalho","year":"2017","journal-title":"Magn Reson Imaging Clin N Am."},{"issue":"2","key":"B7-20260618","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/S0041-1345(00)00840-X","article-title":"Gadolinium dimeglumine: an alternative contrast agent for digital subtraction angiography in patients with renal failure","volume":"32","author":"Hammer","year":"2000","journal-title":"Transplant Proc."},{"issue":"1","key":"B8-20260618","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s12880-021-00600-9","article-title":"Patterns of use, effectiveness and safety of gadolinium contrast agents: a European prospective cross-sectional multicentre observational study","volume":"21","author":"Jakobsen","year":"2021","journal-title":"BMC Med Imaging."},{"issue":"3","key":"B9-20260618","doi-asserted-by":"crossref","first-page":"2400269","DOI":"10.1002\/gch2.202400269","article-title":"Gadolinium-based contrast agents (GBCAs) for MRI: a benefit-risk balance analysis from a chemical, biomedical, and environmental point of view","volume":"9","author":"Scarciglia","year":"2025","journal-title":"Glob Chall."},{"issue":"1","key":"B10-20260618","doi-asserted-by":"crossref","first-page":"58","DOI":"10.3390\/molecules27010058","article-title":"How the chemical properties of GBCAs influence their safety profiles in vivo","volume":"27","author":"Do","year":"2021","journal-title":"Molecules."},{"issue":"5","key":"B11-20260618","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/jmri.23725","article-title":"MRI contrast agents: basic chemistry and safety","volume":"36","author":"Hao","year":"2012","journal-title":"J Magn Reson Imaging."},{"issue":"2","key":"B12-20260618","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1039\/C8MT00302E","article-title":"The biological fate of gadolinium-based MRI contrast agents: a call to action for bioinorganic chemists","volume":"11","author":"Le Fur","year":"2019","journal-title":"Metallomics."},{"issue":"6","key":"B13-20260618","doi-asserted-by":"crossref","first-page":"561","DOI":"10.34067\/KID.0000272019","article-title":"Gadolinium-based contrast agent use, their safety, and practice evolution","volume":"1","author":"Do","year":"2020","journal-title":"Kidney360."},{"issue":"2","key":"B14-20260618","first-page":"25","article-title":"Fibrosing skin condition among patients with renal disease--United States and Europe, 1997-2002","volume":"51","year":"2002","journal-title":"MMWR Morb Mortal Wkly Rep."},{"issue":"9234","key":"B15-20260618","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/S0140-6736(00)02694-5","article-title":"Scleromyxoedema-like cutaneous diseases in renal-dialysis patients","volume":"356","author":"Cowper","year":"2000","journal-title":"Lancet."},{"issue":"4","key":"B16-20260618","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1093\/ndt\/gfk062","article-title":"Gadolinium--a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?","volume":"21","author":"Grobner","year":"2006","journal-title":"Nephrol Dial Transplant."},{"key":"B17-20260618","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ejps.2015.02.016","article-title":"Distribution profile of gadolinium in gadolinium chelate-treated renally-impaired rats: role of pharmaceutical formulation","volume":"72","author":"Fretellier","year":"2015","journal-title":"Eur J Pharm Sci."},{"issue":"3","key":"B18-20260618","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1148\/radiol.15150025","article-title":"Intracranial gadolinium deposition after contrast-enhanced MR imaging","volume":"275","author":"McDonald","year":"2015","journal-title":"Radiology."},{"issue":"2","key":"B19-20260618","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s00261-020-02670-9","article-title":"Characteristics of gadolinium-based contrast media cancellation at the point of care: a 15-month assessment of FDA-Inspired medication guides on gadolinium retention","volume":"46","author":"O\u2019Donohue","year":"2021","journal-title":"Abdom Radiol (NY)."},{"issue":"7","key":"B20-20260618","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.3174\/ajnr.A4615","article-title":"Gadolinium-based contrast agent accumulation and toxicity: an update","volume":"37","author":"Ramalho","year":"2016","journal-title":"AJNR Am J Neuroradiol."},{"issue":"6","key":"B21-20260618","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1097\/00002281-200311000-00017","article-title":"Nephrogenic fibrosing dermopathy: the first 6 years","volume":"15","author":"Cowper","year":"2003","journal-title":"Curr Opin Rheumatol."},{"issue":"11","key":"B22-20260618","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1093\/ndt\/gfr085","article-title":"Multiorgan gadolinium (Gd) deposition and fibrosis in a patient with nephrogenic systemic fibrosis--an autopsy-based review","volume":"26","author":"Sanyal","year":"2011","journal-title":"Nephrol Dial Transplant."},{"issue":"9","key":"B23-20260618","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1111\/j.1442-2042.2012.03042.x","article-title":"Recent topics related to nephrogenic systemic fibrosis associated with gadolinium-based contrast agents","volume":"19","author":"Kitajima","year":"2012","journal-title":"Int J Urol."},{"issue":"10","key":"B24-20260618","doi-asserted-by":"crossref","first-page":"3433","DOI":"10.1002\/art.22925","article-title":"Cutaneous changes of nephrogenic systemic fibrosis: predictor of early mortality and association with gadolinium exposure","volume":"56","author":"Todd","year":"2007","journal-title":"Arthritis Rheum."},{"issue":"3","key":"B25-20260618","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1053\/j.ackd.2011.03.001","article-title":"Nephrogenic systemic fibrosis and gadolinium-based contrast agents","volume":"18","author":"Abu-Alfa","year":"2011","journal-title":"Adv Chronic Kidney Dis."},{"issue":"4","key":"B26-20260618","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1111\/j.1365-2133.2011.10465.x","article-title":"Nephrogenic systemic fibrosis is found only among gadolinium-exposed patients with renal insufficiency: a case-control study from Denmark","volume":"165","author":"Elmholdt","year":"2011","journal-title":"Br J Dermatol."},{"issue":"3","key":"B27-20260618","doi-asserted-by":"crossref","first-page":"484","DOI":"10.2215\/CJN.06580909","article-title":"Low risk for nephrogenic systemic fibrosis in nondialysis patients who have chronic kidney disease and are investigated with gadolinium-enhanced magnetic resonance imaging","volume":"5","author":"Chrysochou","year":"2010","journal-title":"Clin J Am Soc Nephrol."},{"issue":"35","key":"B28-20260618","doi-asserted-by":"crossref","first-page":"e293","DOI":"10.3346\/jkms.2020.35.e293","article-title":"Late onset nephrogenic systemic fibrosis in a patient with stage 3 chronic kidney disease: a case report","volume":"35","author":"Lim","year":"2020","journal-title":"J Korean Med Sci."},{"issue":"3","key":"B29-20260618","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/j.1365-2133.2007.08369.x","article-title":"Gadolinium-induced nephrogenic systemic fibrosis in a patient with an acute and transient kidney injury","volume":"158","author":"Kalb","year":"2008","journal-title":"Br J Dermatol."},{"issue":"1","key":"B30-20260618","doi-asserted-by":"crossref","first-page":"W17","DOI":"10.2214\/AJR.11.8144","article-title":"Nephrogenic systemic fibrosis","volume":"199","author":"Kaewlai","year":"2012","journal-title":"AJR Am J Roentgenol."},{"issue":"5","key":"B31-20260618","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10157-008-0063-4","article-title":"Chronic inflammation and accelerated atherosclerosis as important cofactors in nephrogenic systemic fibrosis following intravenous gadolinium exposure","volume":"12","author":"Grebe","year":"2008","journal-title":"Clin Exp Nephrol."},{"issue":"10","key":"B32-20260618","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1111\/j.1600-6143.2007.01941.x","article-title":"Gadolinium is not the only trigger for nephrogenic systemic fibrosis: insights from two cases and review of the recent literature","volume":"7","author":"Wahba","year":"2007","journal-title":"Am J Transplant."},{"issue":"6","key":"B33-20260618","doi-asserted-by":"crossref","first-page":"e0129720","DOI":"10.1371\/journal.pone.0129720","article-title":"An updated study to determine association between gadolinium-based contrast agents and nephrogenic systemic fibrosis","volume":"10","author":"Zhang","year":"2015","journal-title":"PLoS One."},{"issue":"2","key":"B34-20260618","doi-asserted-by":"crossref","first-page":"586","DOI":"10.2214\/AJR.06.1094","article-title":"Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned","volume":"188","author":"Broome","year":"2007","journal-title":"AJR Am J Roentgenol."},{"issue":"2","key":"B35-20260618","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/01.rli.0000253505.88945.d5","article-title":"Nephrogenic systemic fibrosis: a review of 6 cases temporally related to gadodiamide injection (omniscan)","volume":"42","author":"Khurana","year":"2007","journal-title":"Invest Radiol."},{"issue":"1","key":"B36-20260618","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1148\/radiol.2531082160","article-title":"Nephrogenic systemic fibrosis after gadopentetate dimeglumine exposure: case series of 36 patients","volume":"253","author":"Abujudeh","year":"2009","journal-title":"Radiology."},{"issue":"1","key":"B37-20260618","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/PREACCEPT-4280658695831343","article-title":"Gadolinium-enhanced cardiovascular magnetic resonance: administered dose in relationship to United States Food and Drug Administration (FDA) guidelines","volume":"14","author":"Nacif","year":"2012","journal-title":"J Cardiovasc Magn Reson."},{"issue":"3","key":"B38-20260618","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1148\/radiol.2483071863","article-title":"Incidence of nephrogenic systemic fibrosis at two large medical centers","volume":"248","author":"Prince","year":"2008","journal-title":"Radiology."},{"issue":"2","key":"B39-20260618","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/MNH.0000000000000475","article-title":"Gadolinium-based contrast agents: why nephrologists need to be concerned","volume":"28","author":"Leyba","year":"2019","journal-title":"Curr Opin Nephrol Hypertens."},{"issue":"3","key":"B40-20260618","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1148\/radiol.10091131","article-title":"Effect of different classes of gadolinium-based contrast agents on control and nephrogenic systemic fibrosis-derived fibroblast proliferation","volume":"256","author":"Edward","year":"2010","journal-title":"Radiology."},{"issue":"5","key":"B41-20260618","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1002\/path.2311","article-title":"Gadodiamide contrast agent \u2018activates\u2019 fibroblasts: a possible cause of nephrogenic systemic fibrosis","volume":"214","author":"Edward","year":"2008","journal-title":"J Pathol."},{"issue":"1","key":"B42-20260618","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/RLI.0b013e31815e6277","article-title":"A preclinical study to investigate the development of nephrogenic systemic fibrosis: a possible role for gadolinium-based contrast media","volume":"43","author":"Sieber","year":"2008","journal-title":"Invest Radiol."},{"issue":"2","key":"B43-20260618","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1002\/jmri.25625","article-title":"Gadolinium-based contrast agents: a comprehensive risk assessment","volume":"46","author":"Fraum","year":"2017","journal-title":"J Magn Reson Imaging."},{"issue":"3","key":"B44-20260618","doi-asserted-by":"crossref","first-page":"e2330036","DOI":"10.2214\/AJR.23.30036","article-title":"Update on gadolinium-based contrast agent safety, from the AJR special series on contrast media","volume":"223","author":"Starekova","year":"2024","journal-title":"AJR Am J Roentgenol."},{"issue":"2","key":"B45-20260618","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1148\/radiol.2019191158","article-title":"Virtual elimination of nephrogenic systemic fibrosis: a medical success story with a small asterisk","volume":"292","author":"Davenport","year":"2019","journal-title":"Radiology."},{"issue":"2","key":"B46-20260618","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1148\/radiol.2019182916","article-title":"A systematic review of 639 patients with biopsy-confirmed nephrogenic systemic fibrosis","volume":"292","author":"Attari","year":"2019","journal-title":"Radiology."},{"issue":"10","key":"B47-20260618","doi-asserted-by":"crossref","first-page":"895","DOI":"10.3109\/10408444.2014.955568","article-title":"The role of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: a critical update","volume":"44","author":"Id\u00e9e","year":"2014","journal-title":"Crit Rev Toxicol."},{"issue":"5","key":"B48-20260618","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1097\/PAI.0b013e3181de372e","article-title":"Immunohistochemical aspects of the fibrogenic pathway in nephrogenic systemic fibrosis","volume":"18","author":"Quatresooz","year":"2010","journal-title":"Appl Immunohistochem Mol Morphol."},{"issue":"1","key":"B49-20260618","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/RCT.0b013e31805d08ee","article-title":"Nephrogenic systemic fibrosis\/nephrogenic fibrosing dermopathy: a primer for radiologists","volume":"32","author":"Prasad","year":"2008","journal-title":"J Comput Assist Tomogr."},{"issue":"12","key":"B50-20260618","doi-asserted-by":"crossref","first-page":"e82037","DOI":"10.1371\/journal.pone.0082037","article-title":"Nephrogenic systemic fibrosis in Denmark--a nationwide investigation","volume":"8","author":"Elmholdt","year":"2013","journal-title":"PLoS One."},{"issue":"1","key":"B51-20260618","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1102\/1470-7330.2007.0019","article-title":"Nephrogenic systemic fibrosis (NSF): a late adverse reaction to some of the gadolinium based contrast agents","volume":"7","author":"Thomsen","year":"2007","journal-title":"Cancer Imaging."},{"issue":"4","key":"B52-20260618","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1053\/j.ajkd.2020.07.012","article-title":"Risks and options with gadolinium-based contrast agents in patients with CKD: a review","volume":"77","author":"Rudnick","year":"2021","journal-title":"Am J Kidney Dis."},{"issue":"8","key":"B53-20260618","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1177\/02841851231171660","article-title":"The need for prophylactic hemodialysis to protect against nephrogenic systemic fibrosis in patients with end-stage renal disease receiving gadolinium-based contrast agents","volume":"64","author":"Lee","year":"2023","journal-title":"Acta Radiol."},{"issue":"10","key":"B55-20260618","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.2215\/CJN.0000000729","article-title":"Gadolinium and kidney disease: should we still be cautious?","volume":"20","author":"Wahba","year":"2025","journal-title":"Clin J Am Soc Nephrol."},{"issue":"2","key":"B56-20260618","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1001\/jamainternmed.2019.5284","article-title":"Risk of nephrogenic systemic fibrosis in patients with stage 4 or 5 chronic kidney disease receiving a group II gadolinium-based contrast agent: a systematic review and meta-analysis","volume":"180","author":"Woolen","year":"2020","journal-title":"JAMA Intern Med."},{"issue":"2","key":"B57-20260618","doi-asserted-by":"crossref","first-page":"110","DOI":"10.7326\/M20-0299","article-title":"Risk for nephrogenic systemic fibrosis after exposure to newer gadolinium agents: a systematic review","volume":"173","author":"Lunyera","year":"2020","journal-title":"Ann Intern Med."},{"issue":"9","key":"B58-20260618","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/RLI.0000000000000462","article-title":"10 years of nephrogenic systemic fibrosis: a comprehensive analysis of nephrogenic systemic fibrosis reports received by a pharmaceutical company from 2006 to 2016","volume":"53","author":"Endrikat","year":"2018","journal-title":"Invest Radiol."},{"issue":"2","key":"B59-20260618","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1365-2133.2007.08335.x","article-title":"Dermal inorganic gadolinium concentrations: evidence for in vivo transmetallation and long-term persistence in nephrogenic systemic fibrosis","volume":"158","author":"Abraham","year":"2008","journal-title":"Br J Dermatol."},{"issue":"1","key":"B60-20260618","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jaad.2006.10.048","article-title":"Gadolinium deposition in nephrogenic fibrosing dermopathy","volume":"56","author":"Boyd","year":"2007","journal-title":"J Am Acad Dermatol."},{"issue":"1","key":"B61-20260618","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jaad.2006.10.047","article-title":"Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis","volume":"56","author":"High","year":"2007","journal-title":"J Am Acad Dermatol."},{"issue":"4","key":"B62-20260618","doi-asserted-by":"crossref","first-page":"968","DOI":"10.2215\/CJN.00100108","article-title":"Ultrastructural evidence of dermal gadolinium deposits in a patient with nephrogenic systemic fibrosis and end-stage renal disease","volume":"3","author":"Schroeder","year":"2008","journal-title":"Clin J Am Soc Nephrol."},{"issue":"4","key":"B63-20260618","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.2214\/AJR.07.2822","article-title":"Gadolinium-based contrast exposure, nephrogenic systemic fibrosis, and gadolinium detection in tissue","volume":"190","author":"Wiginton","year":"2008","journal-title":"AJR Am J Roentgenol."},{"issue":"8","key":"B64-20260618","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1056\/NEJMcpc0708697","article-title":"Case records of the Massachusetts general hospital. Case 6-2008. A 46-year-old woman with renal failure and stiffness of the joints and skin","volume":"358","author":"Kay","year":"2008","journal-title":"N Engl J Med."},{"issue":"5","key":"B65-20260618","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.rcl.2009.06.005","article-title":"Nephrogenic systemic fibrosis: histology and gadolinium detection","volume":"47","author":"Thakral","year":"2009","journal-title":"Radiol Clin North Am."},{"issue":"7","key":"B66-20260618","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1111\/1754-9485.13581","article-title":"Where does the gadolinium go? A review into the excretion and retention of intravenous gadolinium","volume":"67","author":"Sharma","year":"2023","journal-title":"J Med Imaging Radiat Oncol."},{"issue":"1","key":"B67-20260618","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1148\/radiol.2015142690","article-title":"Gadolinium-based contrast agent accumulates in the brain Even in subjects without severe renal dysfunction: evaluation of autopsy brain specimens with inductively coupled plasma mass spectroscopy","volume":"276","author":"Kanda","year":"2015","journal-title":"Radiology."},{"issue":"10","key":"B68-20260618","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.1007\/s00204-025-04124-x","article-title":"Gadolinium toxicity: mechanisms, clinical manifestations, and nanoparticle role","volume":"99","author":"Domingo","year":"2025","journal-title":"Arch Toxicol."},{"issue":"8","key":"B69-20260618","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1097\/RLI.0000000000000977","article-title":"Gadolinium deposition disease: current state of knowledge and expert opinion","volume":"58","author":"Semelka","year":"2023","journal-title":"Invest Radiol."},{"issue":"2","key":"B70-20260618","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1148\/radiol.2021211349","article-title":"Symptoms associated with gadolinium exposure (SAGE): a suggested term","volume":"302","author":"McDonald","year":"2022","journal-title":"Radiology."},{"issue":"11","key":"B71-20260618","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1097\/RLI.0000000000001160","article-title":"Symptoms associated with gadolinium exposure: different patterns and rates between linear and macrocyclic gadolinium-based contrast agents","volume":"60","author":"Shahid","year":"2025","journal-title":"Invest Radiol."},{"key":"B72-20260618","doi-asserted-by":"crossref","first-page":"1376587","DOI":"10.3389\/ftox.2024.1376587","article-title":"The safety of magnetic resonance imaging contrast agents","volume":"6","author":"Cunningham","year":"2024","journal-title":"Front Toxicol."},{"issue":"1","key":"B73-20260618","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-28666-1","article-title":"The onset of rare earth metallosis begins with renal gadolinium-rich nanoparticles from magnetic resonance imaging contrast agent exposure","volume":"13","author":"DeAguero","year":"2023","journal-title":"Sci Rep."},{"key":"B74-20260618","doi-asserted-by":"crossref","first-page":"110383","DOI":"10.1016\/j.mri.2025.110383","article-title":"Precipitation of gadolinium from magnetic resonance imaging contrast agents may be the brass tacks of toxicity","volume":"119","author":"Henderson","year":"2025","journal-title":"Magn Reson Imaging."},{"issue":"1","key":"B75-20260618","doi-asserted-by":"crossref","first-page":"21731","DOI":"10.1038\/s41598-021-00974-4","article-title":"An NMR relaxometry approach for quantitative investigation of the transchelation of gadolinium ions from GBCAs to a competing macromolecular chelator","volume":"11","author":"Werner","year":"2021","journal-title":"Sci Rep."},{"issue":"10","key":"B76-20260618","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1016\/j.jid.2019.03.1145","article-title":"Nephrogenic systemic fibrosis is mediated by myeloid C-C chemokine receptor 2","volume":"139","author":"Do","year":"2019","journal-title":"J Invest Dermatol."},{"key":"B77-20260618","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.taap.2019.05.009","article-title":"Gadolinium-based contrast agents: stimulators of myeloid-induced renal fibrosis and major metabolic disruptors","volume":"375","author":"Do","year":"2019","journal-title":"Toxicol Appl Pharmacol."},{"issue":"11","key":"B78-20260618","first-page":"1","article-title":"Gadolinium intermediate elimination and persistent symptoms after magnetic resonance imaging contrast agent exposure","volume":"42","author":"Brent Wagner","year":"2025","journal-title":"Fed Pract."},{"issue":"5","key":"B79-20260618","first-page":"218","article-title":"Gadolinium deposition disease: a case report and the prevalence of enhanced MRI procedures within the veterans health administration","volume":"39","author":"Jackson","year":"2022","journal-title":"Fed Pract."},{"key":"B80-20260618","doi-asserted-by":"crossref","first-page":"110612","DOI":"10.1016\/j.mri.2026.110612","article-title":"Response to Dr. Do","volume":"128","author":"Wagner","year":"2026","journal-title":"Magn Reson Imaging."},{"issue":"1","key":"B81-20260618","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s10565-025-10014-w","article-title":"Early endolysosomal dysfunction is a contributing factor to gadolinium-based contrast agent mouse renal proximal tubule epithelial cell injury","volume":"41","author":"DeAguero","year":"2025","journal-title":"Cell Biol Toxicol."},{"issue":"9","key":"B82-20260618","doi-asserted-by":"crossref","first-page":"3026","DOI":"10.1096\/fj.201500188R","article-title":"Centrality of bone marrow in the severity of gadolinium-based contrast-induced systemic fibrosis","volume":"30","author":"Drel","year":"2016","journal-title":"FASEB J."},{"issue":"1","key":"B83-20260618","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1148\/radiol.10092000","article-title":"Intravenous contrast medium-induced nephrotoxicity: is the medical risk really as great as we have come to believe?","volume":"256","author":"Katzberg","year":"2010","journal-title":"Radiology"},{"issue":"4","key":"B84-20260618","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.jvir.2022.11.022","article-title":"Adverse events associated with intra-arterial administration of gadolinium-based contrast agents: a systematic review and meta-analysis","volume":"34","author":"MacLeod","year":"2023","journal-title":"J Vasc Interv Radiol."},{"issue":"6","key":"B85-20260618","doi-asserted-by":"crossref","first-page":"378","DOI":"10.5152\/dir.2018.18172","article-title":"Nephrotoxicity of gadolinium-based contrast in the setting of renal artery intervention: retrospective analysis with 10-year follow-up","volume":"24","author":"Takahashi","year":"2018","journal-title":"Diagn Interv Radiol."},{"issue":"1","key":"B86-20260618","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1212\/CPJ.0000000000000696","article-title":"Neurotoxicity from intrathecal gadolinium administration: case presentation and brief review","volume":"10","author":"Calvo","year":"2020","journal-title":"Neurol Clin Pract."},{"issue":"4","key":"B87-20260618","doi-asserted-by":"crossref","first-page":"F617","DOI":"10.1152\/ajprenal.00456.2020","article-title":"Overlapping roles of NADPH oxidase 4 for diabetic and gadolinium-based contrast agent-induced systemic fibrosis","volume":"320","author":"Bruno","year":"2021","journal-title":"Am J Physiol Renal Physiol."},{"issue":"1","key":"B88-20260618","doi-asserted-by":"crossref","first-page":"F1","DOI":"10.1152\/ajprenal.00166.2016","article-title":"Pathophysiology of gadolinium-associated systemic fibrosis","volume":"311","author":"Wagner","year":"2016","journal-title":"Am J Physiol Ren Physiol."},{"issue":"6","key":"B89-20260618","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1016\/j.ajpath.2012.08.026","article-title":"Nephrogenic systemic fibrosis: evidence for oxidative stress and bone marrow-derived fibrocytes in skin, liver, and heart lesions using a 5\/6 nephrectomy rodent model","volume":"181","author":"Wagner","year":"2012","journal-title":"Am J Pathol."}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.0000001115","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:42:35Z","timestamp":1786369355000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.0000001115"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,18]]},"references-count":87,"URL":"https:\/\/doi.org\/10.2215\/cjn.0000001115","relation":{},"ISSN":["1555-9041","1555-905X"],"issn-type":[{"value":"1555-9041","type":"print"},{"value":"1555-905X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,18]]}}}